The National Immunobiological Company (Nacimbio), part of Rostec, has signed the agreement with Mylan Laboratories, which is a part of Mylan NV (US).
"We are starting cooperation with India's Mylan Laboratories. This will provide us with the supply of substances, transfer of technology and the creation of modern combination drugs for HIV treatment," Rostec CEO Sergei Chemezov said in a statement.
As a result, the cost of such drugs in the Russian market will significantly decrease, he added.
The agreement between the two entities was inked at Biotechmed-2017.
Disclaimer: No Business Standard Journalist was involved in creation of this content